CDC Loses Faith In AstraZeneca's Nasal Spray Flu Vaccine
Executive Summary
The US Centers for Disease Control and Prevention has decided not to recommend AstraZeneca PLC's nasal spray flu vaccine FluMist Quadrivalent (known as Fluenz Tetra in Europe) for the upcoming flu season owing to lack of efficacy. AstraZeneca said it would take an $80m write-down on stocks in the second quarter as a result.